Drug Profile
Anti-CD19 chimeric antigen receptor T cell therapy - Tianjin Mycure Medical Technology
Alternative Names: Anti-CD19 CAR-T cells therapy - Tianjin Mycure Medical Technology; CD19 CAR-T cellsLatest Information Update: 06 Jan 2022
Price :
$50
*
At a glance
- Originator Tianjin Mycure Medical Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in China (Parenteral)
- 07 Sep 2018 Phase-I clinical trials in Precursor B cell lymphoblastic leukaemia-lymphoma in China (Parenteral) (NCT03671460)